These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 16406701

  • 1. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.
    Int J Pharm; 2006 Feb 17; 309(1-2):87-93. PubMed ID: 16406701
    [Abstract] [Full Text] [Related]

  • 2. PEG-interferon conjugates: effects of length and structure of linker.
    Sabar MF, Kausar S, Zafar AU.
    Pak J Pharm Sci; 2013 Mar 17; 26(2):425-30. PubMed ID: 23455218
    [Abstract] [Full Text] [Related]

  • 3. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha.
    Vyas SP, Rawat M, Rawat A, Mahor S, Gupta PN.
    Drug Dev Ind Pharm; 2006 Jul 17; 32(6):699-707. PubMed ID: 16885125
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
    Cai Y, Zhang Z, Fan K, Zhang J, Shen W, Li M, Si D, Luo H, Zeng Y, Fu P, Liu C.
    Regul Pept; 2012 Jan 10; 173(1-3):74-81. PubMed ID: 21985916
    [Abstract] [Full Text] [Related]

  • 5. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
    Ramon J, Saez V, Baez R, Aldana R, Hardy E.
    Pharm Res; 2005 Aug 10; 22(8):1374-86. PubMed ID: 16078148
    [Abstract] [Full Text] [Related]

  • 6. [Interferon alpha-2b modified with polyethylene glycol].
    Wu Y, Zhai Y, Lei J, Ma G, Su Z.
    Sheng Wu Gong Cheng Xue Bao; 2008 Sep 10; 24(9):1658-63. PubMed ID: 19160853
    [Abstract] [Full Text] [Related]

  • 7. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Sep 10; 16(1):200-7. PubMed ID: 15656592
    [Abstract] [Full Text] [Related]

  • 8. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR.
    Semin Liver Dis; 2004 Sep 10; 24 Suppl 2():33-8. PubMed ID: 15346244
    [Abstract] [Full Text] [Related]

  • 9. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan 10; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 10. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.
    Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M.
    Bioconjug Chem; 2001 Jan 10; 12(2):195-202. PubMed ID: 11312680
    [Abstract] [Full Text] [Related]

  • 11. [Obtaining and characteristics of domestic preparation interferon alpha-2b with prolonged effect].
    Pokholenko IaA, Porubleva LV, Dubeĭ IIa, Rebriev AV, Sutugina LP, Gromovoĭ TIu, Pokrovskiĭ VA, Obolenskaia MIu, Chernykh SI.
    Ukr Biokhim Zh (1999); 2008 Jan 10; 80(6):92-100. PubMed ID: 19351063
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA, FarmaPEG Study Group.
    BMC Pharmacol; 2010 Nov 23; 10():15. PubMed ID: 21092287
    [Abstract] [Full Text] [Related]

  • 13. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM, Chan LJ, Ryan GM, Porter CJ, Kaminskas LM.
    J Pharm Sci; 2015 Apr 23; 104(4):1421-30. PubMed ID: 25631360
    [Abstract] [Full Text] [Related]

  • 14. Pegylation of IFN-alpha and antiviral activity.
    Boulestin A, Kamar N, Sandres-Sauné K, Alric L, Vinel JP, Rostaing L, Izopet J.
    J Interferon Cytokine Res; 2006 Dec 23; 26(12):849-53. PubMed ID: 17238827
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
    Brennan BJ, Xu ZX, Grippo JF.
    Clin Ther; 2012 Sep 23; 34(9):1883-91. PubMed ID: 22858176
    [Abstract] [Full Text] [Related]

  • 16. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
    Spolaore B, Raboni S, Satwekar AA, Grigoletto A, Mero A, Montagner IM, Rosato A, Pasut G, Fontana A.
    Bioconjug Chem; 2016 Nov 16; 27(11):2695-2706. PubMed ID: 27731976
    [Abstract] [Full Text] [Related]

  • 17. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
    Zheng L, Li MP, Gou ZP, Wang Y, Xu N, Cai YM, Luo H.
    Br J Clin Pharmacol; 2015 Apr 16; 79(4):650-9. PubMed ID: 25297637
    [Abstract] [Full Text] [Related]

  • 18. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
    Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R.
    J Interferon Cytokine Res; 2001 Dec 16; 21(12):1103-15. PubMed ID: 11798469
    [Abstract] [Full Text] [Related]

  • 19. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity.
    Lee BK, Kwon JS, Kim HJ, Yamamoto S, Lee EK.
    Bioconjug Chem; 2007 Dec 16; 18(6):1728-34. PubMed ID: 17941681
    [Abstract] [Full Text] [Related]

  • 20. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.
    Chan LJ, Feeney OM, Leong NJ, McLeod VM, Porter CJH, Williams CC, Kaminskas LM.
    Biomacromolecules; 2017 Sep 11; 18(9):2866-2875. PubMed ID: 28731677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.